ResMed Stock-Based Comp decreased by 7.4% to $26.79M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.1%, from $24.12M to $26.79M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 9.4% CAGR.
other_share_based_compensation| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.90M | $17.30M | $16.10M | $15.86M | $15.99M | $16.92M | $16.46M | $17.83M | $19.93M | $18.51M | $19.84M | $20.44M | $21.39M | $20.16M | $22.63M | $24.12M | $24.75M | $21.16M | $28.94M | $26.79M |
| QoQ Change | — | +2.4% | -6.9% | -1.5% | +0.8% | +5.8% | -2.7% | +8.3% | +11.7% | -7.1% | +7.2% | +3.0% | +4.6% | -5.8% | +12.3% | +6.6% | +2.6% | -14.5% | +36.8% | -7.4% |
| YoY Change | — | — | — | — | -5.3% | -2.2% | +2.3% | +12.4% | +24.6% | +9.4% | +20.5% | +14.6% | +7.4% | +8.9% | +14.1% | +18.0% | +15.7% | +5.0% | +27.9% | +11.1% |